Market Cap: $585.82M
ZI
Zevra Therapeutics, Inc.
ZVRA
NASDAQ (NASDAQ Global Select)USD
Market Cap: $585.82M
Leadership Confidence at Zevra Therapeutics Highlighted by Insider Transaction Zevra Therapeutics observes a significant insider transaction that underscores the confidence its leadership has in the c…
Zevra Therapeutics Divests SDX Portfolio to Commave Therapeutics for $50 Million Zevra Therapeutics announces that Commave Therapeutics SA acquires its serdexmethylphenidate (SDX) portfolio for $50 mi…
Zevra Therapeutics Transfers ADHD Assets to Commave Therapeutics in Strategic Move Zevra Therapeutics makes a significant strategic shift by announcing the acquisition of its serdexmethylphenidate (SD…
Innovative Approaches in Niemann-Pick Disease Type C Treatment Zevra Therapeutics focuses its efforts on addressing the challenges posed by Niemann-Pick disease type C (NPC), a rare and inherited neur…
Zevra Therapeutics Pursues Strategic Innovations amid Market Trends As the biotechnology sector navigates a complex landscape influenced by shifting market dynamics, Zevra Therapeutics focuses on deve…
Zevra Therapeutics Focuses on Advancements in Specialized Treatments Amid Market Fluctuations Zevra Therapeutics, dedicated to developing innovative therapies for patients with rare diseases, continue…
### Zevra Therapeutics Prepares for Significant Earnings Announcement Zevra Therapeutics is on the cusp of an important milestone with the upcoming release of its quarterly earnings report on March 9,…
Zevra Therapeutics Focuses on Innovative Solutions Amid Market Uncertainty Zevra Therapeutics continues to make strides in the biopharmaceutical sector as it pivots toward innovative treatments design…
Zevra Therapeutics Eyes Market Expansion Amidst Industry Challenges Zevra Therapeutics, a company dedicated to developing innovative therapies for rare diseases, is currently focused on expanding its…
Zevra Therapeutics Gears Up for Quarterly Earnings Report Amid Promising Growth Zevra Therapeutics prepares to unveil its quarterly earnings report on August 12, 2025, signaling a crucial moment for t…
Zevra Therapeutics Prepares for Critical Earnings Report Amid Promising Growth Zevra Therapeutics (ZVRA) gears up to release its quarterly earnings report on August 12, 2025, amidst a backdrop of stro…
Zevra Therapeutics Prepares for Key Earnings Report Amid Positive Growth Trends Zevra Therapeutics (ZVRA) stands on the brink of releasing its quarterly earnings report, set for August 12, 2025. This…
Zevra Therapeutics: A Strong Quarter Signals Promising Future Zevra Therapeutics Inc. demonstrates robust performance in its first-quarter financial results, which exceed analysts’ expectations and re…
Zevra Therapeutics Delivers Strong First-Quarter Financial Results, Signaling Growth Potential Zevra Therapeutics Inc. demonstrates robust financial health in its latest quarterly report, exceeding an…
Zevra Therapeutics Showcases Strong Financial Performance Amid Strategic Growth Initiatives Zevra Therapeutics Inc. (ZVRA) demonstrates significant progress in its operational strategies, as reflected…